Sugi Predict

Sugi Predict / Compounds / SCHEMBL657724

SCHEMBL657724

SCHEMBL657724

O=C1CC(c2ccc(Cl)cc2)CC(=O)O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 4/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ ALOX12 P18054 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ MAP1LC3B Q9GZQ8 1/20 0.49
▸ KMT2A Q03164 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ CTRB1 P17538 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10017608 0.89 CTRB1 (0.53) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL10017611 0.83 CTRB1 (0.49) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL16536124 0.82 KMT2A (0.44) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL16536123 0.82 KMT2A (0.44) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL425308 0.80 POLB (0.58) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL5239565 0.80 ALDH1A1 (0.46) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL13829416 0.79 MAPT (0.61) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL658679 0.79 MAP1LC3B (0.49) ALDH1A1MAP1LC3BKMT2ACTRB1PLAU
SCHEMBL2471171 0.79 MAP1LC3B (0.50) POLBALDH1A1MAP1LC3BKMT2AMAPT
SCHEMBL7105128 0.79 CTRB1 (0.39) POLBALDH1A1SMN1; SMN2ALOX12HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114891194-B Double-functional polymer catalyst for synthesizing polyester and application thereof 中国科学院长春应用化学研究所 2023-08-29 — — CN claimed
CN-116122057-A High-strength cold-resistant textile for aerospace use and manufacturing method thereof 西京学院 2023-05-16 — — CN claimed
CN-114891194-A Difunctional high-molecular catalyst for synthesizing polyester and application thereof 中国科学院长春应用化学研究所 2022-08-12 — — CN claimed
CN-111393630-B Polymer polyol and preparation method thereof 中国科学院长春应用化学研究所 2022-06-07 — — CN claimed
CN-108752575-B Preparation method of polyester material 中国科学院长春应用化学研究所 2020-08-25 — — CN claimed
CN-111393630-A Polymer polyol and preparation method thereof 中国科学院长春应用化学研究所 2020-07-10 — — CN claimed
US-12404265-B2 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2025-09-02 — — US disclosed
WO-2025076088-A1 LACTAMS FOR USE AS SARM1 INHIBITORS GENENTECH, INC. (US) 2025-04-10 — — WO disclosed
CN-119528923-A Tri-fused ring compound and preparation method and application thereof 韦恩生物科技有限公司 2025-02-28 — — CN disclosed
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2024-04-30 — — US disclosed
US-20240116901-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2024-04-11 — — US disclosed
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2023-10-26 — — US disclosed
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2023-10-26 — — US disclosed
US-6649613-B1 Integrin inhibitors MERCK PATENT GMBH (DE) 2003-11-18 — — US disclosed
EP-1194401-B1 DIACYLHYDRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2003-09-10 — — EP disclosed
EP-1194401-A1 DIACYLHYDRAZINE DERIVATIVES MERCK PATENT GmbH (DE) 2002-04-10 — — EP disclosed
WO-2001005753-A1 DIACYLHYDRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2001-01-25 — — WO disclosed
US-4309541-A CHEMICAL INTERMEDIATES TO QUINAZOLINE HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1982-01-05 — — US disclosed
US-4255429-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1981-03-10 — — US disclosed
EP-0009465-A1 N-(1-(4-amino-2-quinazolinyl)-3 or 4-piperidyl lactames, process for their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1980-04-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404265-B2 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 POLB 2207/4885ALDH1A1 3991/4885SMN1; SMN2 7/4885
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 POLB 2207/4885ALDH1A1 3991/4885SMN1; SMN2 7/4885
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 POLB 2207/4885ALDH1A1 3991/4885SMN1; SMN2 7/4885
US-20240116901-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 POLB 2207/4885ALDH1A1 3991/4885SMN1; SMN2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.